H.R. 830 118th Congress
HELP Copays Act
- Health
- Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1]
- Congress.gov ↗
Latest action, Feb 17, 2023: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
142 cosponsors
Sponsored by Rep. Carter, Earl L. "Buddy" [R-GA-1] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
104 D · 38 R
- Democrat
- Republican
- Independent
Referred to: House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
8 reports
ABBVIE, INC.
FEDERAL STREET STRATEGIES, LLC
8 reports
ALLIANCE FOR PATIENT ACCESS
8 reports
8 reports
8 reports
8 reports
8 reports
8 reports
BLUE CROSS BLUE SHIELD OF ARIZONA
MEHLMAN CONSULTING, INC.
8 reports
BRISTOL-MYERS SQUIBB
CROSSROADS STRATEGIES, LLC
8 reports
8 reports
8 reports
CROHN'S & COLITIS FOUNDATION
8 reports
8 reports
DYSTONIA MEDICAL RESEARCH FOUNDATION
HEALTH AND MEDICINE COUNSEL
8 reports
All 25 of 103 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ABBVIE INC. | 8 | $8.2M | Q1 2023 | Q3 2024 | yes | |
| ABBVIE, INC. | FEDERAL STREET STRATEGIES, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| ALLIANCE FOR PATIENT ACCESS | 8 | $160K | Q1 2023 | Q3 2024 | yes | |
| AMERICAN COLLEGE OF RHEUMATOLOGY | 8 | $770K | Q1 2023 | Q3 2024 | yes | |
| AMERICAN MEDICAL ASSOCIATION | 8 | $44.9M | Q1 2023 | Q3 2024 | yes | |
| AMGEN INC | 8 | $22.9M | Q1 2023 | Q3 2024 | yes | |
| ARTHRITIS FOUNDATION | 8 | $725K | Q1 2023 | Q3 2024 | yes | |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 8 | $1.8M | Q1 2023 | Q3 2024 | yes | |
| BLUE CROSS BLUE SHIELD OF ARIZONA | MEHLMAN CONSULTING, INC. | 8 | $320K | Q1 2023 | Q3 2024 | yes |
| BRISTOL-MYERS SQUIBB | CROSSROADS STRATEGIES, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| BRISTOL-MYERS SQUIBB COMPANY | 8 | $14.2M | Q1 2023 | Q3 2024 | yes | |
| CHRONIC CARE POLICY ALLIANCE | 8 | $1.0M | Q1 2023 | Q3 2024 | yes | |
| CROHN'S & COLITIS FOUNDATION | 8 | $390K | Q1 2023 | Q3 2024 | yes | |
| CYSTIC FIBROSIS FOUNDATION | 8 | $1.7M | Q1 2023 | Q3 2024 | yes | |
| DYSTONIA MEDICAL RESEARCH FOUNDATION | HEALTH AND MEDICINE COUNSEL | 8 | $80K | Q1 2023 | Q3 2024 | yes |
| EMD SERONO INC | 8 | $5.4M | Q1 2023 | Q3 2024 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 8 | $9.9M | Q1 2023 | Q3 2024 | yes | |
| HEMOPHILIA OF GEORGIA | NELSON MULLINS RILEY & SCARBOROUGH | 8 | $160K | Q1 2023 | Q3 2024 | yes |
| INFUSION PROVIDERS ALLIANCE | 8 | $216K | Q1 2023 | Q3 2024 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 8 | $14.6M | Q1 2023 | Q3 2024 | yes | |
| LUNDBECK LLC | 8 | $1.0M | Q1 2023 | Q3 2024 | yes | |
| MERCK & CO INC | 8 | $19.2M | Q1 2023 | Q3 2024 | yes | |
| MERCK & CO., INC. | CROSSROADS STRATEGIES, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| NATIONAL ALOPECIA AREATA FOUNDATION | HEALTH AND MEDICINE COUNSEL | 8 | $80K | Q1 2023 | Q3 2024 | yes |
| NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION) | ARTEMIS POLICY GROUP LLC | 8 | $400K | Q1 2023 | Q3 2024 | yes |